Malignant Mesothelioma - Pipeline Review, H2 2012

Global Markets Direct, July 2012, Pages: 237

Malignant Mesothelioma – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Malignant Mesothelioma - Pipeline Review, H2 2012', provides an overview of the Malignant Mesothelioma therapeutic pipeline. This report provides information on the therapeutic development for Malignant Mesothelioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Malignant Mesothelioma. 'Malignant Mesothelioma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Malignant Mesothelioma.
- A review of the Malignant Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Malignant Mesothelioma pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Malignant Mesothelioma.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Malignant Mesothelioma pipeline depth and focus of Malignant Mesothelioma therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Malignant Mesothelioma Therapeutic Products under Development, Key Players in Malignant Mesothelioma Therapeutics, Malignant Mesothelioma Pipeline Overview, Malignant Mesothelioma Pipeline, Malignant Mesothelioma Pipeline Assessment

2
List of Tables 5
List of Figures 6
Introduction 8
REPORT COVERAGE 8
Malignant Mesothelioma Overview 9
Therapeutics Development 10
An Overview of Pipeline Products for Malignant Mesothelioma 10
Malignant Mesothelioma Therapeutics under Development by Companies 12
Malignant Mesothelioma Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 19
Comparative Analysis 19
Mid Clinical Stage Products 20
Comparative Analysis 20
Early Clinical Stage Products 21
Comparative Analysis 21
Discovery and Pre-Clinical Stage Products 22
Comparative Analysis 22
Malignant Mesothelioma Therapeutics – Products under Development by Companies 23
Malignant Mesothelioma Therapeutics – Products under Investigation by Universities/Institutes 24
Companies Involved in Malignant Mesothelioma Therapeutics Development 30
Viralytics Ltd. 30
Merck & Co., Inc. 31
Oxford BioMedica plc 32
Plexxikon Inc. 33
Pfizer Inc. 34
Aduro BioTech 35
Aeolus Pharmaceuticals, Inc. 36
AEterna Zentaris Inc. 37
Bionomics Limited 38
Morphotek, Inc. 39
CanBas Co., Ltd. 40
MolMed S.p.A. 41
Y's Therapeutics Co., Ltd. 42
Oncolys BioPharma Inc. 43
Polaris Group 44
Malignant Mesothelioma – Therapeutics Assessment 45
Assessment by Monotherapy Products 45
Assessment by Combination Products 46
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 52
CBP501 - Drug Profile 52
TroVax - Drug Profile 54
AEOL 10150 - Drug Profile 56
NGR-hTNF - Drug Profile 59
OBP-801 - Drug Profile 61
NGR-hTNF + Doxorubicin - Drug Profile 62
SDX-102 - Drug Profile 64
Cavatak - Drug Profile 65
YS110 - Drug Profile 68
BNC105 - Drug Profile 69
MORAb-009 - Drug Profile 70
IMC-A12 - Drug Profile 72
Valproate Acid + Doxorubicin - Drug Profile 73
Vatalanib - Drug Profile 74
Velcade + Cisplatin - Drug Profile 75
Azacitidine + Temozolomide - Drug Profile 76
Cisplatin + Interferon Alfa + Radiation Therapy - Drug Profile 77
Megestrol - Drug Profile 79
Cisplatin + Alimta + Gleevec - Drug Profile 80
BMS-354825 - Drug Profile 82
Palliative Therapy + Vinorelbine - Drug Profile 84
Avastin + Tarceva - Drug Profile 85
Semaxanib - Drug Profile 86
Porfimer sodium + Pleuropneumonectomy - Drug Profile 88
Pemetrexed Disodium + Cisplatin + Radiation Therapy - Drug Profile 89
DetoxPC + Cyclophosphamide - Drug Profile 91
Pemetrexed + Cisplatin + Avastin - Drug Profile 92
SU11248 - Drug Profile 93
Pazopanib - Drug Profile 94
CBP501 + Cisplatin + Pemetrexed - Drug Profile 96
Gemcitabine + Cisplatin - Drug Profile 98
Bevacizumab + Cisplatin + Gemcitabine Hydrochloride - Drug Profile 100
BAY 43-9006 - Drug Profile 102
BG00001 - Drug Profile 103
PLX 3397 - Drug Profile 104
ADI-PEG 20 - Drug Profile 106
Zolinza - Drug Profile 108
NGR-hTNF + Gemcitabine - Drug Profile 110
NGR-hTNF + Vinorelbine - Drug Profile 111
PF-03446962 - Drug Profile 113
BG00001 - Drug Profile 114
Sorafenib + Pemetrexed + Cisplatin - Drug Profile 115
GW786034 - Drug Profile 117
Cyclophosphamide + Vaccine Therapy - Drug Profile 118
Pemetrexed + Gemcitabine - Drug Profile 120
Dasatinib - Drug Profile 122
Pemetrexed + Cisplatin - Drug Profile 123
Cisplatin + Gemcitabine - Drug Profile 124
Xeloda - Drug Profile 125
MORAb-009 + Pemetrexed + Cisplatin - Drug Profile 126
Cisplatin + Pemetrexed + Bevacizumab - Drug Profile 128
Bevacizumab + Pemetrexed + Carboplatin - Drug Profile 129
RAD001 - Drug Profile 131
Valproate + Doxorubicin - Drug Profile 133
Alimta + Gemzar - Drug Profile 134
Wilms Tumor Gene mRNA Transfected Autologous Dendritic Cell Vaccine - Drug Profile 136
Gemcitabine + Cisplatin - Drug Profile 138
Pemetrexed - Drug Profile 139
Cediranib maleate - Drug Profile 140
Cediranib Maleate - Drug Profile 141
rIFN-Alpha-2b + Cisplatin + Radiation Therapy - Drug Profile 142
Celecoxib + Decitabine + FK228 - Drug Profile 143
L-alanosine - Drug Profile 145
Amg 102 + Cisplatin + Pemetrexed Disodium - Drug Profile 146
Sutent - Drug Profile 148
CRS-207 - Drug Profile 149
Cisplatin + Gemcitabine + Amifostine + Sodium Thiosulfate - Drug Profile 151
FR901228 + Flavopiridol - Drug Profile 153
CP-870893 + Cisplatin + Pemetrexed - Drug Profile 154
Cyclophosphamide + Pemetrexed - Drug Profile 156
Cyclophosphamide + Cisplatin + Pemetrexed - Drug Profile 157
Cyclophosphamide + Carboplatin + Pemetrexed - Drug Profile 159
GC1008 - Drug Profile 161
BNC105P - Drug Profile 162
Cisplatin + Pemetrexed Disodium - Drug Profile 163
Cisplatin + Pemetrexed + Radiation Therapy - Drug Profile 165
Bortezomib - Drug Profile 166
K562-GM Vaccine + Cyclophosphamide + Celecoxib - Drug Profile 167
Zoledronic Acid - Drug Profile 169
Lung Tumor Associated Antigen + DetoxPC + Cyclophosphamide - Drug Profile 170
SS1(dsFv)-PE38 Immunotoxin + Cisplatin + Pemetrexed Disodium - Drug Profile 171
Autologous Dendritic Cells Pulsed With Tumor Lysate - Drug Profile 173
Axitinib + Cisplatin + Pemetrexed - Drug Profile 174
SCH 721015 - Drug Profile 175
Cediranib Maleate + Cisplatin + Pemetrexed - Drug Profile 176
Oxaliplatin + Gemcitabine - Drug Profile 178
Velcade + Eloxatin - Drug Profile 179
Cisplatin + Pemetrexed - Drug Profile 180
Palliative Therapy + Mitomycin + Vinblastine + Cisplatin - Drug Profile 181
Pemetrexed Disodium + Gemcitabine - Drug Profile 183
Vinorelbine5 - Drug Profile 184
Erbitux + Cisplatin - Drug Profile 185
Cisplatin - Drug Profile 186
L-NDDP - Drug Profile 188
Mitomycin + Vincristine + Cisplatin - Drug Profile 189
Gemcitabine + Cisplatin - Drug Profile 191
Autologous Tumor Cell Vaccine + Iscomatrix + Celecoxib - Drug Profile 192
Thalidomide - Drug Profile 193
ADI-PEG 20 - Drug Profile 194
Cisplatin + Pemetrexed - Drug Profile 195
Cisplatin + Pemetrexed + Vorinostat - Drug Profile 196
Autologous Mesothelin Re-Directed T Cells - Drug Profile 197
Pentostatin + Cyclophosphamide + SS1P - Drug Profile 198
Raltitrexed + Cisplatin + Radiation Therapy - Drug Profile 199
Dendritic Cell-Based Immunotherapy + Cyclophosphamide - Drug Profile 200
Malignant Mesothelioma Therapeutics – Drug Profile Updates 201
Malignant Mesothelioma Therapeutics – Discontinued Products 217
Malignant Mesothelioma Therapeutics - Dormant Products 218
Malignant Mesothelioma – Product Development Milestones 223
Featured News & Press Releases 223
Appendix 229
Methodology 229
Coverage 229
Secondary Research 229
Primary Research 229
Expert Panel Validation 229
Contact Us 230
Disclaimer 230

List of Tables
Number of Products Under Development for Malignant Mesothelioma, H2 2012 17
Products under Development for Malignant Mesothelioma – Comparative Analysis, H2 2012 18
Number of Products under Development by Companies, H2 2012 20
Number of Products under Development by Companies, H2 2012 (Contd..1) 21
Number of Products under Investigation by Universities/Institutes, H2 2012 23
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 24
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 25
Comparative Analysis by Late Stage Development, H2 2012 26
Comparative Analysis by Mid Clinical Stage Development, H2 2012 27
Comparative Analysis by Early Clinical Stage Development, H2 2012 28
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 29
Products under Development by Companies, H2 2012 30
Products under Investigation by Universities/Institutes, H2 2012 31
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 32
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 33
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 34
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 35
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 36
Viralytics Ltd., H2 2012 37
Merck & Co., Inc., H2 2012 38
Oxford BioMedica plc, H2 2012 39
Plexxikon Inc., H2 2012 40
Pfizer Inc., H2 2012 41
Aduro BioTech, H2 2012 42
Aeolus Pharmaceuticals, Inc., H2 2012 43
AEterna Zentaris Inc., H2 2012 44
Bionomics Limited, H2 2012 45
Morphotek, Inc., H2 2012 46
CanBas Co., Ltd., H2 2012 47
MolMed S.p.A., H2 2012 48
Y's Therapeutics Co., Ltd., H2 2012 49
Oncolys BioPharma Inc., H2 2012 50
Polaris Group, H2 2012 51
Assessment by Monotherapy Products, H2 2012 52
Assessment by Combination Products, H2 2012 53
Assessment by Stage and Route of Administration, H2 2012 55
Assessment by Stage and Molecule Type, H2 2012 58
Malignant Mesothelioma Therapeutics – Drug Profile Updates 208
Malignant Mesothelioma Therapeutics – Discontinued Products 224
Malignant Mesothelioma Therapeutics – Dormant Products 225
Malignant Mesothelioma Therapeutics – Dormant Products (Contd..1) 226
Malignant Mesothelioma Therapeutics – Dormant Products (Contd..2) 227
Malignant Mesothelioma Therapeutics – Dormant Products (Contd..3) 228
Malignant Mesothelioma Therapeutics – Dormant Products (Contd..4) 229

List of Figures
Number of Products under Development for Malignant Mesothelioma, H2 2012 17
Products under Development for Malignant Mesothelioma – Comparative Analysis, H2 2012 18
Products under Development by Companies, H2 2012 19
Products under Investigation by Universities/Institutes, H2 2012 22
Late Stage Products, H2 2012 26
Mid Clinical Stage Products, H2 2012 27
Early Clinical Stage Products, H2 2012 28
Discovery and Pre-Clinical Stage Products, H2 2012 29
Assessment by Monotherapy Products, H2 2012 52
Assessment by Combination Products, H2 2012 53
Assessment by Route of Administration, H2 2012 54
Assessment by Stage and Route of Administration, H2 2012 55
Assessment by Molecule Type, H2 2012 56
Assessment by Stage and Molecule Type, H2 2012 57

Customers who bought this item also bought

• Bladder Cancer - Pipeline Review, H2 2012
• Cervical Cancer - Pipeline Review, H2 2012
• Malignant Pleural Effusion - Pipeline Review, H2 2012
• Brain Cancer - Pipeline Review, H2 2012
• Lymphoma - Pipeline Review, H2 2012
• Acute Pain - Pipeline Review, H2 2012
• Metastatic Colorectal Cancer - Pipeline Review, H2 2012
• Adenocarcinoma - Pipeline Review, H2 2012
• Pulmonary Fibrosis - Pipeline Review, H2 2012
• Anemia - Pipeline Review, H2 2012